AIMT stock news

AIMT has developed a 'desensitivity' treatment for peanut allergies….AIMT Read more
Aimmune Therapeutics Inc (NASDAQ: AIMT )'s peanut allergy product candidate Palforzia to treat peanut allergy in children and adolescents has received the backing of an FDA panel that reviewed the NDA. Following the positive verdict, H.C. Wainwright looked at what the decision means for DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT ), which has a competing drug in late-stage development. The Analyst Andrew Fein reiterated a Buy rating on DBV with a $25 price target. The Thesis Friday's Adcom meeting validated safety concerns over Aimmune's AR101 treatment, with its peanut protein exposure possibly resulting in anaphylaxis reactions during therapy, Fein said in a Monday note. (See his track record here .) Anaphylaxis is a serious allergic reaction that occurs quickly and could cause death. The point about anaphylaxis arising from AR101 treatment that could necessitate epinephrine treatment could … Full story available on Read more
Aimmune's (AIMT) peanut allergy drug gets majority of votes from the Advisory Committee of the FDA. Read more
Aimmune Therapeutics is hlated as the FDA conducts an efficacy meeting on the company's peanut allergy treatment candidate Palforzia….AIMT Read more
The company's peanut allergen desensitization therapy took an indirect step forward. Read more
Aimmune Therapeutics Inc (NASDAQ: AIMT ) shares have been on an extended downtrend since the start of 2018. This thinly traded, small-cap biotech is on the radar ahead of a key FDA panel meeting scheduled for Friday, Sept. 13. Brisbane, California-based Aimmune, founded in June 2011, is a clinical-stage biopharma company focusing on the development of drugs for food allergies. It employes 215 people full-time, with roughly half of them in R&D. Market Opportunity Over 30 million people across the U.S. and Europe suffer from food allergies, according to estimates shared by the company. Among food allergies, peanut allergies are the most frequently occurring, causing serious outcomes and life-threatening events. About 3 million people in both the U.S. and Europe are allergic to peanuts, and there is no approved therapy to treat food allergies or prevent their symptoms. Staying away from allergic food is recommended for those who are allergic. In the case of accidental exposure that may trigger a serious allergic reaction, treatment with antihistamines or injectable epinephrine is recommended. Read more
Jim Cramer takes a look at Waste Management, Vail Resorts, Aimmune Therapeutics, Comstock Resources, B&G Foods and more….MTN Read more
Investors need to pay close attention to Aimmune (AIMT) stock based on the movements in the options market lately. Read more
Shares of small-cap biopharma company DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT) were advancing strongly Thursday in reaction to an announcement regarding a … Read more
Aimmune's (AIMT) peanut allergy candidate AR101 attracts negative review from ICER, stating risks outweighs benefits in patients. AR101 is under review and a decision is expected by January 2020. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on July 11) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Masimo Corporation (NASDAQ: MASI ) Novocure Ltd (NASDAQ: NVCR ) Penumbra Inc (NYSE: PEN ) SAGE Therapeutics Inc (NASDAQ: SAGE ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 11) Aimmune Therapeutics Inc (NASDAQ: AIMT )(fell on a release from the Institute for Clinical and Economic Review, which expressed skepticism about peanut allergy drug vis-à-vis avoiding the food altogether) Amneal Pharmaceuticals Inc (NYSE: AMRX ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) Iradimed Corp (NASDAQ: IRMD ) See Also: Attention Biotech Investors: Mark Your Calendar For These … Full story available on Read more
Aimmune Therapeutics (AIMT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Read more

Proudly made at